We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Hypercoagulability Evaluated in New‐Onset Systemic Lupus Erythematosus Patients

By LabMedica International staff writers
Posted on 30 Dec 2019
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that involves T cell, B cell, and dendritic cell dysfunction, as well as antinuclear autoantibody production. More...
Several clinical and scientific studies of SLE indicate an increased risk of thrombosis in these cases.

The traditional parameters for screening coagulopathy include prothrombin time (PT) and activated partial thromboplastin time (aPTT). The thromboelastography (TEG) procedure facilitates the functional evaluation of the coagulation cascade, from clot formation to clot lysis, and provides data on the entire coagulation system.

Medical scientists at the Shanghai Jiao Tong University School of Medicine (Shanghai, China) enrolled in a study a total of 41 patients with new‐onset SLE who had not undergone treatment were enrolled, and 56 healthy individuals were included as controls. Blood samples were collected using 18G needles and vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) (for complete blood cell count) and 3.2% trisodium citrate (for TEG and coagulation analyses). Moreover, 24‐hour urine collection was performed in a clean dry container.

Complete blood counts were obtained using an automated hematology analyzer DXH800 (Beckman Coulter, Brea, CA, USA). The reference range for PLT count was 101‐320 × 109/L. Routine coagulation screening assays, including PT, aPTT, fibrinogen (Fg), thrombin time (TT), d‐dimer (DD), and fibrinogen/fibrin degradation products (FDP), were performed in all the patients using an automated coagulometer CS5100 (Sysmex Corporation, Kobe, Japan). Lupus anticoagulant (LAC) status was examined using ACL‐TOP700 (Instrumentation Laboratory, Bedford, MA, USA). Blood clot formation and stability were evaluated via TEG tests using a thromboelastography analyzer (Haemonetics Corporation, Braintree, MA, USA).

The team reported that there was a significant difference in the TEG reaction time and TEG achievement of clot firmness between the groups. Moreover, these parameters were correlated with the lupus anticoagulant levels, platelet count, 24‐hour urinary total protein quantity, and systemic lupus erythematosus disease activity index ((SLEDAI). The TEG parameters were correlated with other clinical and laboratory data, such as LAC status, PLT level, and urinary total protein (UTP) and SLEDAI values. Patients with positive LAC status, higher PLT levels, UTP >500 mg/24 hours and higher SLEDAI values are known to have a greater risk of thrombosis.

The authors concluded that they have demonstrated the prospective value of TEG in evaluating hypercoagulability in patients with SLE. The study was published on December 16, 2019 in the Journal of Clinical Laboratory Analysis.

Related Links:
Shanghai Jiao Tong University School of Medicine
Beckman Coulter
Sysmex Corporation
Instrumentation Laboratory
Haemonetics Corporation



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.